Audited Financial Results for the quarter and financial year ended March 31, 2026

Revenue Growth 20pctPat NegativeEbitda Margin CompressionEmphasis Of MatterResults View source PDF Explain this filing

NIVABUPA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.0%Reaction day

₹81.29

prior close

₹84.40

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.1%+4.0% vs market

General Insurance peers, median of 5sector-0.0%+3.0% vs sector

On the reaction day the stock moved 4.0 pts more than Nifty Smallcap 250 and 3.0 pts more than its General Insurance peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.8

10m

+4.9

15m

+3.8

30m

+3.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.0-1.1+4.0-0.0+3.0

Next day

+2.8-4.0+6.8-1.9+4.7

+1.5-3.7+5.2-1.6+3.1

-1.4-3.7+2.3+0.6-2.0

-1.6-4.1+2.5+0.6-2.2

-1.6-5.5+3.9-1.0-0.6

+0.4-4.4+4.7-0.4+0.7

15d

+3.3-2.8+6.1-4.0+7.3

+1.7-4.6+6.2-5.5+7.2

+8.4+4.2+4.2-1.8+10.1

+4.9+5.4-0.5-9.8+14.8

UpDownMarket · Nifty Smallcap 250Sector · General Insurance peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Niva Bupa Health Insurance Company reported audited financial results for Q4 and FY26. Gross Direct Premium grew 27% YoY to Rs 8.59 lakh lakh in FY26 from Rs 6.76 lakh lakh. However, Profit After Tax declined 39% to Rs 13,078 lakh from Rs 21,352 lakh due to combined ratio above 100% (103.39%) indicating claims and expenses exceeded earned premiums. Q4 performance was strong with PAT jumping 67% YoY to Rs 34,513 lakh. The EOM ratio improved from 39.22% in FY25 to 33.70% in FY26, though auditors flagged in Emphasis of Matter that the company has applied for forbearance from IRDAI regarding EOM exceeding allowable limits for FY24-25. Solvency ratio remains healthy at 2.49x. Joint statutory auditors issued unmodified opinion.

Likely market impact

Positive Q4 recovery signals improving operational efficiency but FY26 PAT decline and combined ratio above 100% indicate ongoing margin pressure. The pending IRDAI forbearance decision on EOM regulations adds regulatory uncertainty. Healthy solvency provides buffer but shareholders should monitor cost containment measures.